Braun David A, Chakraborty Abhishek A
Center of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine, 300 George Street (Suite 6400), New Haven, CT 06511, USA.
Department of Cancer Biology, Lerner Research Institute, Cleveland Clinical, 9500 Euclid Avenue (NB40), Cleveland, OH 44195, USA; Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH 44106, USA.
Hematol Oncol Clin North Am. 2023 Oct;37(5):827-840. doi: 10.1016/j.hoc.2023.04.012. Epub 2023 May 26.
The treatment of advanced renal cell carcinoma (RCC) has changed dramatically with immune checkpoint inhibitors, yet most patients do not have durable responses. There is consequently a tremendous need for novel therapeutic development. RCC, and particularly the most common histology clear cell RCC, is an immunobiologically and metabolically distinct tumor. An improved understanding of RCC-specific biology will be necessary for the successful identification of new treatment targets for this disease. In this review, we discuss the current understanding of RCC immune pathways and metabolic dysregulation, with a focus on topics important for future clinical development.
免疫检查点抑制剂的出现使晚期肾细胞癌（RCC）的治疗发生了巨大变化，但大多数患者的反应并不持久。因此，迫切需要开发新的治疗方法。RCC，尤其是最常见的组织学类型透明细胞RCC，是一种在免疫生物学和代谢方面具有独特性的肿瘤。要成功识别该疾病的新治疗靶点，有必要更好地了解RCC特异性生物学。在这篇综述中，我们讨论了目前对RCC免疫途径和代谢失调的理解，重点关注对未来临床发展至关重要的主题。
